This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Hypoglycemia	*Protein kinase Bβ* (*PKBB*; *AKT2*)	Human genomic studies identified a mutation in *AKT2* that could play a role in severe recurrent hypoglycemia. In three patients with the condition, genomic sequencing identified a gain-of-function mutation in *AKT2*, which regulates glucose transport in cell metabolism and growth. In normal human cell lines, insulin or vehicle resulted in cell membrane localization of the mutant *AKT2*, whereas only insulin resulted in cell membrane localization of wild-type *AKT2*. Planned work includes studies in primary cells from patients to elucidate the disease biology and identify potential therapeutic targets. *SciBX* 4(40); doi:10.1038/scibx.2011.1116 Published online Oct. 13, 2011	Unpatented; available for partnering	Hussain, K. *et al. Science*; published online Oct. 6, 2011; doi:10.1126/science.1210878 **Contact:** Robert K. Semple, University of Cambridge Metabolic Research Laboratories, Cambridge, U.K. e-mail: rks16@cam.ac.uk